We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CS5001

News List

Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting PRNewswire
December 09, 2024
CStone Pharmaceuticals , an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced today the presentation of the latest clinical data for CS5001.
CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in-class ROR1-targeting ADC by the U.S. Food and Drug Administration prnasia
January 04, 2022
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies...
CStone presents research data of CS5001 (ROR1 ADC) at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021 prnasia
October 13, 2021
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines...